BTIG Maintains Buy on Mustang Bio, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin maintains a Buy rating on Mustang Bio (NASDAQ:MBIO) but has lowered the price target from $20 to $16.

August 15, 2023 | 3:33 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mustang Bio's price target has been lowered from $20 to $16 by BTIG, though the Buy rating is maintained.
The lowering of the price target by BTIG could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Buy rating indicates that the analyst still sees potential in the company, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100